Aquestive Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-15
- Employees
- 135
- Market Cap
- $421.6M
- Website
- http://www.aquestive.com
- Introduction
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
Pharmacokinetics Study of DESF in Adults with Oral Allergy Syndrome
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Aquestive Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT06527937
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover Study
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Aquestive Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT03953820
- Locations
- 🇺🇸
Bioclinica Research, Orlando, Florida, United States
🇺🇸Florida Premier Research Institute, LLC, Winter Park, Florida, United States
🇺🇸Clinical Trials of Florida, LLC, Miami, Florida, United States
Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Aquestive Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT03679975
- Locations
- 🇺🇸
University of Florida Center for Movement Disorders & Neuroscience, Gainesville, Florida, United States
Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Aquestive Therapeutics
- Registration Number
- NCT03457753
- Locations
- 🇺🇸
Texas Neurology, P.A., Dallas, Texas, United States
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Aquestive Therapeutics
- Target Recruit Count
- 149
- Registration Number
- NCT03428360
- Locations
- 🇺🇸
OnSite Clinical Solutions LLC, Charlotte, North Carolina, United States
🇺🇸Consultants in Epilepsy and Neurology, PLLC, Boise, Idaho, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Aquestive Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03222349
- Locations
- 🇺🇸
NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Onsite Clinical Solutions LLC, Charlotte, North Carolina, United States
Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Aquestive Therapeutics
- Target Recruit Count
- 35
- Registration Number
- NCT03179891
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸Rancho Research Institute, Downey, California, United States
Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Aquestive Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT01220167